European Access Academy
A multi-stakeholder initiative aiming to facilitate and support the development of a joint European value framework for the assessment of innovative health technologies
The European Access Academy (EAA) aims to identify key challenges and provide sound input for the implementation of the EU HTA Regulation to help achieve the EC’s mission of improving patient access to life saving innovative technologies.
The EAA Faculty is a member of the European Commission's HTA Stakeholder Network.
THANK YOU for joining the
EAA Spring Convention 2024
'EU HTA - Finding the Right Balance'
at Erasmus University, Rotterdam.
We had excellent, heated and very fruitful and constructive discusssions with our expert panel (including
Bernhard Wörmann, Antonella Cardone, Maiwenn Al, Stefan Lange, Francesco Pignatti, Elisabeth de Vries, Laetitia Mariani, Carin Uyl-de Groot, Michael Ermisch and our co-host Maureen Rutten-van Mölken), and all our virtual and on-site participants.
Many thanks to all who contributed!
We look forward to continuing the dialogue as we approach the implementation of the EU HTAR:
Save the Date of our Fall Convention in Rome
(October 24/25).
NOW AVAILABLE:
Video Recordings of all impulse presentations are available HERE
and the EAA Convention Proceedings Issue #5
(click image to download the pdf)
EAA News & Media Posts
April 17, 2024: EAA Faculty Statement on the HTA CG Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Treatment Comparisons
On 8 March the Member State Coordination Group on HTA (HTA CG) adopted this new guideline, which has the objective to "describe the methods currently available for direct and indirect treatment comparisons regarding their underlying assumptions, strengths, and weaknesses", pursuant to Article 3(7), point (d), of the Regulation (EU) 2021/2282 on Health Technology Assessment. The outcomes of the EAA Faculty's thorough review and heated discussions on the guideline are summarised in this statement. One main conclusion is that considering the multiplicity and the heterogeneity of expected EU HTA PICO schemes a thoughtful and rational approach to ‘Best Available Evidence’ should be taken, where the potential of comparative data is to be judged by clear explicit rules.
April 2, 2024: EAA Faculty Feedback on the Draft Implementing Act on JCA
Feb 19, 2024: EAA Post: 'Uncertainty - Friend or Foe'
Feb 06, 2024: EAA Post regarding 'Roadblocks' for EU HTA
Jan 15, 2024: EAA Post regarding the EU HTA Implementing Acts
New manuscript just published:
The EAA's fourth publication, on the outcomes of discussions on stakeholder involvement at the EAA Fall Convention 2022, is now available:
The EAA is an initiative hosted by Copenhagen University, Utrecht University, Vlerick Business School, Agència de Qualitat I Avaluació Sanitàries de Catalunya, Erasmus University and endorsed & funded by:
Springer Healthcare, Abbvie, AstraZeneca, Bayer, Novartis, Pfizer, Roche, Sanofi , vfa, leem and efpia.